The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis
- PMID: 11276275
- DOI: 10.1097/00004836-200104000-00008
The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis
Abstract
Background: Chronic pancreatitis often culminates in maldigestion and diabetes. Clinical management is complex as the correction of maldigestion often disturbs diabetic control.
Study: In the following study, we examined the effects of a potent new commercial pancreatic enzyme on food absorption and blood glucose control. Enzymes were manufactured in enteric-coated mini-microsphere form (0.7--1.6 mm), designed to prevent gastric acid degradation and facilitate co-migration with food, and given in quantities calculated to cover normal digestion requirements (four capsules with meals, two with snacks; content/capsule: lipase 10,000 USP units, protease 37,500 units, amylase 33,200 units). Forty patients with chronic pancreatitis were screened during a run-in nonenzyme-supplemented phase; only those with stool fat excretion rates over 10 g/d (n = 29) were advanced to a 14-day parallel randomized placebo versus enzyme supplement group comparison.
Results: Of these, 62% were diabetic (50% insulin-dependent) and 52% were malnourished (body mass index less than 20 kg/m(2) ). After enzyme supplementation, stool fat and nitrogen excretion decreased, whereas fat absorption increased from 54.0 +/- 9.7% to 80.8 +/- 3.8% per day (p = 0.002) and protein from 80.5 +/- 3.4% to 86.8 +/- 2.2% per day (p = 0.004). Changing treatment from active enzyme supplementation to placebo (and vice versa) resulted in major problems with glucose control; blood glucose levels became abnormal in 28 of 29 patients, one patient required hospitalization for symptomatic hypoglycemia (0.9 mmol/L) during placebo treatment, and one developed diabetic ketoacidosis after recommencing active enzyme supplementation.
Conclusions: In conclusion, high-dose pancreatin mini-microspheres improved, but did not normalize, fat absorption, possibly because of the residual influence of diabetes and malnutrition on absorptive function. In view of the brittle nature of blood glucose control in malnourished insulin-dependent patients, enzyme adjustment should be carefully supervised in-hospital.
Similar articles
-
A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency.Aliment Pharmacol Ther. 1999 Jul;13(7):951-7. doi: 10.1046/j.1365-2036.1999.00566.x. Aliment Pharmacol Ther. 1999. PMID: 10383531 Clinical Trial.
-
Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.Am J Gastroenterol. 2010 Oct;105(10):2276-86. doi: 10.1038/ajg.2010.201. Epub 2010 May 25. Am J Gastroenterol. 2010. PMID: 20502447 Clinical Trial.
-
Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.Aliment Pharmacol Ther. 2012 Sep;36(5):426-36. doi: 10.1111/j.1365-2036.2012.05202.x. Epub 2012 Jul 4. Aliment Pharmacol Ther. 2012. PMID: 22762290 Free PMC article. Clinical Trial.
-
Development of pancreatic enzyme microsphere technology and US findings with Pancrease in the treatment of chronic pancreatitis.Int J Pancreatol. 1989;5 Suppl:31-6. Int J Pancreatol. 1989. PMID: 2702248 Review.
-
[Does enzyme substitution therapy reduce pain in chronic pancreatitis?].Ugeskr Laeger. 2005 Apr 25;167(17):1841-4. Ugeskr Laeger. 2005. PMID: 15929329 Review. Danish. No abstract available.
Cited by
-
Pancreatic enzyme replacement therapy in subjects with exocrine pancreatic insufficiency and diabetes mellitus: a real-life, case-control study.Diabetol Metab Syndr. 2024 Feb 9;16(1):39. doi: 10.1186/s13098-024-01265-4. Diabetol Metab Syndr. 2024. PMID: 38331895 Free PMC article.
-
Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis.Oncotarget. 2017 Oct 7;8(55):94920-94931. doi: 10.18632/oncotarget.21659. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212278 Free PMC article.
-
Pancreatic Enzyme Supplements Are Not Effective for Relieving Abdominal Pain in Patients with Chronic Pancreatitis: Meta-Analysis and Systematic Review of Randomized Controlled Trials.Can J Gastroenterol Hepatol. 2016;2016:8541839. doi: 10.1155/2016/8541839. Epub 2016 Apr 24. Can J Gastroenterol Hepatol. 2016. PMID: 27446871 Free PMC article.
-
Structure and function of the exocrine pancreas in patients with type 1 diabetes.Rev Endocr Metab Disord. 2019 Jun;20(2):129-149. doi: 10.1007/s11154-019-09501-3. Rev Endocr Metab Disord. 2019. PMID: 31077020 Review.
-
Exocrine Pancreas Dysfunction in Type 1 Diabetes.Endocr Pract. 2020 Dec;26(12):1505-1513. doi: 10.4158/EP-2020-0295. Endocr Pract. 2020. PMID: 33471743 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical